CanSino Biologics Inc. (CASBF) Research

CanSino Biologics Inc. is a Chinese biotechnology company dedicated to the research, development, manufacturing, and marketing of vaccines within the People's Republic of China. The company's current vaccine pipeline includes prominent candidates such as Convidecia and an inhaled version (Ad5-nCoV for Inhalation), both designed to combat recombinant novel coronavirus disease. They also have Ad5-EBOV, an Ebola virus vaccine, and MCV2 and MCV4, which are developed for preventing N. meningitides infections. CanSino is actively advancing several vaccines through Phase I clinical trials. These include DTcP vaccines for infants and a DTcP Booster vaccine, both intended to provide improved protection against pertussis where primary vaccination efficacy may have diminished. Additionally, a Tdcp vaccine for adolescents and adults is under development for pertussis. Other Phase I trial products encompass PBPV, a protein-based pneumococcal vaccine designed to be effective irrespective of serotype; PCV13i, a pneumococcal conjugate vaccine; and a TB Booster vaccine aimed at individuals previously vaccinated with BCG. Beyond its clinical-stage programs, CanSino Biologics is engaged in the development of various preclinical products. This includes a DTcP-Hib Combo vaccine, CSB012 for adenovirus, CSB013 for ZIKA virus, CSB015 for meningitis, CSB016 for shingles, and CSB107 for polio. CanSino Biologics Inc. was founded in 2009 and maintains its corporate headquarters in Tianjin, China.

Open CanSino Biologics Inc. (CASBF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.